Get informed when a big investor buys or sells
+ FollowUndervalued by 419.6% based on the discounted cash flow analysis.
Loading insider trades…
Loading congress trades…
| Market cap | $8.32 Million |
|---|---|
| Enterprise Value | $-137,675,041.00 |
| Earnings per Share | $-3.74 |
| Beta | 0.85 |
| Outstanding Shares | 35,126,410 |
| P/E Ratio | -0.08 |
|---|---|
| PEG | -0.04 |
| Price to Sales | - |
| Price to Book Ratio | 0.05 |
| Enterprise Value to Revenue | -9.14 |
| Enterprise Value to EBIT | 0.32 |
| Enterprise Value to Net Income | 0 |
| Total Debt to Enterprise | -0.06 |
| Debt to Equity | 0.04 |
No data
No data available for the latest quarter.
No data available for the latest quarter.
Orexo AB (publ) functions as a specialized pharmaceutical company, focusing on the innovation, advancement, and marketing of both conventional medicines and digital therapeutic solutions. Its commercial reach extends across the United St...